The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism

Contemporary Clinical Trials

Volumn 31, Issue 1, 2010, Pages 131-133

  Goldenberg, Neil A ^a,b   Tripputi, Mark ^c   Crowther, Mark ^d   Abshire, Thomas C ^e   DiMichele, Donna ^f   Manco Johnson, Marilyn J ^a   Hiatt, William R ^b,g  

^a Section of Hematology Oncology   (United States)

^b Colorado Prevention Center ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Health Science Center   (Canada)

^e AFLAC   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Section of Vascular Medicine   (United States)

Author keywords

Children; Clinical trial; Parallel cohort; Pediatrics; Prospective cohort; Randomized controlled trial; Thromboembolism; Venous

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY SURGERY; HUMAN; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 73249145243     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.11.006     Document Type: Article

References (9)

1. Friedman L.M., Furberg C.D., and Mets D.L. Fundamentals of clinical trials. 3rd edition (1998), Springer: New York, New York 61-62
2. Olschewski M., Schumacher M., and Davis K.B. Analysis of randomized and non-randomized patients in clinical trials using the comprehensive cohort follow-up study design. Control Clin Trials 13 (1992) 226-239
3. Albert M., Staggers J., Chew P., and Ridker P.M. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 141 (2001) 893-898
4. www.clinicaltrials.gov/ct2/results?term=Kids+DOTT. Accessed June 20, 2009.
5. Hansson L., Hedner T., and Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Pressure 1 (1992) 113-119
6. Prandoni P., Prins M.H., Lensing A.W., Ghirarduzzi A., Ageno W., Imberti D., et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150 (2009) 577-585
7. Büller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 401S-428S
8. Hathaway H.A., Joachim E.L., Jacobson L., Bombardier C., Hathaway W.E., Goldenberg N.A., and Manco-Johnson M.J. In a prospective inceptional cohort study of children with thrombosis, a persistently positive dilute Russell viper venom time is associated with thrombus progression or recurrence and multiple antiphospholipid antibodies. Blood 112 (2008) 527A
9. Monagle P., Chalmers E., Chan A., deVeber G., Kirkham F., Massicotte P., et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133 (2008) 887S-968S